Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Hirofumi Harima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0406-0345; OpenAlex author ID A5080641253. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 7

  1. [Hemosuccus pancreaticus caused by pancreatic cancer treated with radiation therapy for hemostasis]. Co-author DOI 10.11405/nisshoshi.122.130↗
  2. Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-023-11091-y↗
  3. Retraction Note: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-023-11677-6↗
  4. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-020-07167-8↗
  5. Successful endoscopic ultrasound-guided gallbladder drainage through the mesh of a duodenal stent for cholecystitis in a patient with pancreatic cancer. Co-author DOI 10.1111/den.13409↗
  6. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. Co-author DOI 10.18632/oncotarget.25421↗
  7. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. Co-author DOI 10.1186/s12885-016-2744-9↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taro Takami · 6 shared papers, 2016–2025 · strength 0.89
  2. Isao Sakaida · 6 shared papers, 2016–2023 · strength 0.76
  3. Shuhei Shinoda · 5 shared papers, 2016–2023 · strength 0.60
  4. Takahiro Yamasaki · 5 shared papers, 2016–2023 · strength 0.60
  5. Shogo Amano · 4 shared papers, 2018–2023 · strength 0.54
  6. Michitaka Kawano · 1 shared paper, 2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.